Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.4605
+0.0045 (0.99%)
Mar 17, 2026, 10:15 AM EDT - Market open
Gossamer Bio Revenue
Gossamer Bio had revenue of $13.29M in the quarter ending September 30, 2025, with 40.23% growth. This brings the company's revenue in the last twelve months to $44.05M, down -58.17% year-over-year. In the year 2024, Gossamer Bio had annual revenue of $114.70M.
Revenue (ttm)
$44.05M
Revenue Growth
-58.17%
P/S Ratio
2.40
Revenue / Employee
$303,800
Employees
145
Market Cap
106.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 106.83M |
| Fortress Biotech | 62.30M |
| Q32 Bio | 53.74M |
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| Pyxis Oncology | 2.82M |
| Genelux | 8.00K |
GOSS News
- 12 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Benzinga
- 15 days ago - GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 21 days ago - Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript - Seeking Alpha
- 21 days ago - BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75% - GlobeNewsWire
- 21 days ago - Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 21 days ago - Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
- 22 days ago - Gossamer Bio's experimental lung condition drug fails in late-stage trial - Reuters
- 22 days ago - Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire